AUTHORS
Sanya Haiaty, PhD, Hyejin Oh, MS2, Nouran Darras, MS3, Kylee Brewster, MS4, Casey Duncan Saul Katerndahl, PhD5
AFFILIATIONS
1 Indiana University School of Medicine, Indianapolis, Indiana, United States
2 Indiana University School of Medicine, Indianapolis, Indiana, United States
3 Indiana University School of Medicine, Indianapolis, Indiana, United States
4 Indiana University School of Medicine, Indianapolis, Indiana, United States
5 Indiana University School of Medicine, Indianapolis, Indiana, United States
ABSTRACT
Inherited mutations in the transcription factor GATA2 lead to GATA2 deficiency syndrome, which is characterized by opportunistic infections and cytopenias of monocytes, B cells, and NK cells. These patients also have a ~70% chance of developing myelodysplastic syndromes (MDS) and/or acute myeloid leukemia (AML). GATA2T354M is the most common missense mutation in GATA2 deficiency syndrome and shows the strongest association with AML progression. AML-associated GATA2 mutations are heterozygous in 95% of cases; however, the remaining wild-type allele is invariantly epigenetically silenced, resulting in functional hemizygosity. It is currently unclear what the molecular mechanisms are by which GATA2 mutations dysregulated normal hematopoiesis and promote AML.
To answer these questions, we developed a germline Gata2T354M knock-in mouse model. Surprisingly, we found that Gata2T354M/T354M homozygous mice are viable. This is first mouse model in which only a mutated Gata2 allele is expressed, which therefore mimics clinical observations. Flow cytometric analysis demonstrated a 90.0% and 58.3% reduction in long-term hematopoietic stem cells (LT-HSCs) from Gata2T354M/T354M and Gata2T354M/+ mice, respectively, compared to WT mice. Additionally, Gata2T354M/T354M mice exhibited a 66.9% reduction in B cells, which was accompanied by a marked depletion of corresponding progenitor cell populations, including a 93.4% reduction in lymphoid-primed multipotent progenitor (MPP4) cells and an 88.4% reduction in common lymphoid progenitors, suggesting that the loss of GATA2 function impairs early B cell lineage specification and commitment. Single cell RNA sequencing revealed that genes involved in B cell specification and commitment, including Dntt, Flt3, and Il7r, are decreased in Gata2T354M/T354M vs. WT hematopoietic stem and progenitor cells. These findings mirror the cytopenias observed in patients and reveal altered gene expression that may underlie the defects observed in B cell development. We also observed a 56.9% and 58.5% reduction in monocytes and NK cells, respectively, in Gata2T354M/T354M mice compared to WT mice . Therefore, Gata2T354M/T354M mice display clinical features of GATA2 deficiency syndrome, including cytopenias of B cells, monocytes, and NK cells.
We also found that Gata2T354M/+ mice develop an AML-like disease, although with long latency (534 days) and low penetrance (2.2%). This suggests that additional cooperating mutations are necessary for leukemic transformation. One such mutation that co-occurs in 50.4% of GATA2 mutated human AML cases is bi-allelic deletion of the transcription factor CEBPA. Therefore, to determine if Gata2 and Cebpa mutations cooperate to intiate AML and to determine the molecular basis for this potential cooperation, we utilized CRISPR/Cas9 genome editing to induce these bi-allelic Cebpa deletions in bone marrow from Gata2T354M/+ mice followed by transplantation. To determine if loss of the remaining WT Gata2 allele is important in AML development, we also knocked out the remaining WT allele with CRISPR/Cas9. These studies demonstrated that Gata2T354M/+ cooperates with Cebpa-/- to drive AML development with 100% penetrance and a median latency of 229 days. Knockout of the remaining WT Gata2 allele (Gata2T354M/-) significantly reduced the latency by 62.5 days to 166.5 days. Interestingly, whole exome sequencing (WES) of 10 of these leukemias identified several tertiary mutations with high variant allele frequencies (VAFs), including indels in the AML tumor suppressor Kmt2c. We found that 3 of the leukemias had Kmt2c mutations with VAFs of 25.8%, 29.3%, and 33.3%. KMT2C mutations are enriched in CEBPA mutated human AML cases, suggesting that our mouse model might be recapitulating the mutational landscape of AML cases with GATA2 and CEBPA mutations.
Collectively, these findings establish the first murine model that faithfully recapitulates AML initiation driven by an inherited Gata2 mutation and the first model to examine the leukemogenic consequences of Gata2 hemizygosity. Gata2T354M/T354M mice also mimic the B cell, NK cell, and monocyte cytopenias observed in GATA2 deficiency syndrome.
DISCLOSURES
Sanya Haiaty, PhD: No relevant conflicts of interest to declare.